The Biden administration doubled its order of Pfizer’s COVID-19 antiviral drug; California is now the first state to require health insurance plans to cover at-home STI tests; the Supreme Court will hear in-person arguments Friday to decide whether to block federal vaccine mandates.
President Biden announced Tuesday that his administration doubled its order of Pfizer’s COVID-19 antiviral drug, The New York Times reported. The Pfizer pill has been shown to reduce hospitalizations, and this upcoming supply increase will eventually provide enough pills for an additional 10 million Americans, bringing the government’s total order of the drug to 20 million treatment courses. According to a senior administration official, there will be 35,000 additional courses delivered in January and 50,000 more in February, in addition to 350,000 treatment courses that were already expected over the next 2 months. This announcement comes after the US set a global record for COVID-19 cases Monday.
In an effort to address the sexually transmitted infection (STI) epidemic, California is now the first state to require health insurance plans to cover at-home tests for HIV, chlamydia and syphilis, and other STIs, as reported by Kaiser Health News. Part of a broader law, this rule took effect January 1 for people with state-regulated private insurance plans and will go into effect later for the millions of low-income California citizens enrolled in the state’s Medicaid program. Similar to COVID-19 testing kits, some STI tests require patients to send samples to a lab for analysis, while some at-home oral HIV tests give results in a few minutes. Infectious disease experts hope the new rule will bring better disease monitoring to rural and underserved parts of California, reduce the stigma patients experience when seeking care, and give patients more control over their health.
The US Supreme Court will hear in-person arguments Friday in preparation to decide whether to block Biden's vaccine mandates for large businesses and health care workers, Reuters reported. The court will hear from business and religious groups, multiple Republican-led US states, and other groups, with rulings expected soon after. The opposition to the mandates claim the administration is overstepping its authority by establishing vaccine mandates on the federal level. In the past, the Supreme Court has rejected several religious-based challenges to state vaccine requirements, but Friday's cases are the first to address the federal government's authority to issue its own vaccine mandates.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Data analysis showed that 40% of patients who filled a prescription for Wegovy in 2021 or 2022 were still taking it a year later; both Democrats and reproductive rights organizations are pressuring the Biden administration to ensure health insurers fully cover contraception; CMS implemented Medicare changes in March that limited access to blood tests that help transplant recipients ensure their organs remain healthy.
Read More
Insufficient Data, Disparities Plague Lung Cancer Risk Factor Documentation
September 24th 2023On this episode of Managed Care Cast, we speak with the senior author of a study published in the September 2023 issue of The American Journal of Managed Care® on the importance of adequate and effective lung cancer risk factor documentation to determine a patient's eligibility for screening.
Listen
The Impact of Nurse Practitioner Attribution in Medicare Shared Savings ACOs
December 5th 2023Allowing nurse practitioners to serve as attribution-eligible providers for Medicare Shared Savings Program accountable care organizations leads to no change in hierarchical condition category risk scores and modest growth in attributed beneficiaries.
Read More